BhagirathbhaiRavjibhaiDholariaMD

Hematology • Nashville, TN

Hematologic Oncology

Associate Professor, Hematology-Oncology, Vanderbilt University Medical Center

Join to view full profile

Dr. Dholaria is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dholaria's full profile

Already have an account?

Office
2220 Pierce Ave
Nashville, TN 37232
Phone+1 615-875-9731

Summary

I am an associate professor in the department of hematology-oncology (Stem cell Transplant and Cellular Immunotherapy) at Vanderbilt University Medical Center and Nashville VA Medical Center. My area of specialization is hematological malignancies and stem cell transplantation. My primary field of research is adoptive cellular therapies (CAR T-cell therapy) for the treatment of relapsed lymphoid and plasma cell malignancies.

Education & Training

Moffitt Cancer CenterFellowship, Blood & Bone Marrow Transplant, 2017 - 2018
Mayo Clinic College of Medicine and Science (Jacksonville)Fellowship, Hematology and Medical Oncology, 2014 - 2017
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2011 - 2014
B. J. Medical College AhmedabadClass of 2009

Certifications & Licensure

TN State Medical License 2018 - 2025
FL State Medical License 2014 - 2022
AL State Medical License 2020 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Conquer Cancer Foundation Merit Award ASCO, 2018

Clinical Trials

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML Start of enrollment: 2017 Nov 03
Recruiting
Phase 2
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide Start of enrollment: 2023 Jan 18
Recruiting
Phase 1, Phase 2
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Start of enrollment: 2021 Sep 30
Recruiting
Phase 2
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy Start of enrollment: 2017 Dec 29
Recruiting
Phase 3
A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL Start of enrollment: 2022 Jan 14
Active, not recruiting
Phase 1, Phase 2
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Start of enrollment: 2022 Jun 21
Active, not recruiting
Phase 3
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Start of enrollment: 2022 Feb 21
Terminated
Phase 3
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies Start of enrollment: 2022 Nov 01
Recruiting
Phase 2
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma Start of enrollment: 2022 May 05
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

2 citations
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
Blood Advances. 2024-12-10
Progressive multifocal leukoencephalopathy after CAR-T cell therapy.
Michael Montoya, Hannah J Harmsen, Brittney Baer, Nancy Long, Amy Messimore
Bone Marrow Transplantation. 2024-12-01
ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies.
Piyanuch Kongtim, Pongthep Vittayawacharin, Jun Zou, Samer Srour, Brian Shaffer
Transplantation and Cellular Therapy. 2024-12-01

Journal Articles

CMV esophagitis: sequelae of radiation therapy
Khetpal R, Arnaoutakis K, Dholaria B, Esophagus
The great imitator: Psychosis that responded to penicillin
Dholaria B, Pant S, Lavender R, Agarwal A, Canadian Family Physicians

Press Mentions

$‘Off-the-Shelf’ CAR T Therapy Shows Promise for relapsed/refractory Multiple Myeloma$
‘Off-the-Shelf’ CAR T Therapy Shows Promise for relapsed/refractory Multiple MyelomaOctober 4th, 2024
Roche-Poseida Lead Allogeneic CAR-T Advances After Showing Promise in Multiple MyelomaOctober 2nd, 2024
$Poseida Therapeutics Presents Positive Early Results from Its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting$
Poseida Therapeutics Presents Positive Early Results from Its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingDecember 13th, 2023

Professional Memberships

American Society of Hematology - ASH
Member
American Society for Transplantation and Cellular Therapy
Member

Other Languages

Hindi, Gujarati

External Links

VUMC healthhttps://search.vanderbilthealth.com/doctors/dholaria-bhagirathbhai
VUMChttps://medicine.vumc.org/person/bhagirathbhai-dholaria-mbbs
VICChttps://www.vicc.org/member/bhagi-dholaria